Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) Problems Go Beyond Weak Profit
Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) Problems Go Beyond Weak Profit
Last week's earnings announcement from Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) was disappointing to investors, with a sluggish profit figure. We did some analysis, and found that there are some reasons to be cautious about the headline numbers.
上週以嶺藥業有限公司(SZSE:002603)的盈利公告對投資者來說令人失望,利潤增長乏力。 我們進行了一些分析,發現一些理由使得我們對頭條數字保持謹慎。

How Do Unusual Items Influence Profit?
非常規項目如何影響利潤?
Importantly, our data indicates that Shijiazhuang Yiling Pharmaceutical's profit received a boost of CN¥94m in unusual items, over the last year. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Shijiazhuang Yiling Pharmaceutical had a rather significant contribution from unusual items relative to its profit to September 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.
重要的是,我們的數據表明,以嶺藥業去年在飛凡項目上的利潤獲得了9,400萬元人民幣的提振。 雖然盈利增加總是令人高興,但從飛凡項目中獲得巨額貢獻有時會減弱我們的熱情。 當我們分析全球絕大多數上市公司時,我們發現重大的飛凡項目往往不會重複出現。 畢竟,這正是會計術語的含義。 相對於2024年9月的利潤,以嶺藥業在飛凡項目上的貢獻相當顯著。 其他因素相等的情況下,這很可能會導致法定利潤無法很好地指導基本盈利水平。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。
Our Take On Shijiazhuang Yiling Pharmaceutical's Profit Performance
我們對以嶺藥業的盈利表現的看法
As we discussed above, we think the significant positive unusual item makes Shijiazhuang Yiling Pharmaceutical's earnings a poor guide to its underlying profitability. For this reason, we think that Shijiazhuang Yiling Pharmaceutical's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. Sadly, its EPS was down over the last twelve months. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So while earnings quality is important, it's equally important to consider the risks facing Shijiazhuang Yiling Pharmaceutical at this point in time. When we did our research, we found 3 warning signs for Shijiazhuang Yiling Pharmaceutical (1 is potentially serious!) that we believe deserve your full attention.
正如我們上面討論的,我們認爲重要的正面飛凡項目使得以嶺藥業的收益成爲其潛在盈利能力的不良指引。出於這個原因,我們認爲以嶺藥業的法定利潤可能不是其潛在盈利能力的良好指引,並且可能給投資者對該公司的過分正面印象。可悲的是,它的每股收益在過去十二個月下降了。歸根結底,如果您想正確了解公司,除了上述因素外,還有更多要考慮的因素。因此,雖然盈利質量很重要,但同樣重要的是要考慮目前以嶺藥業所面臨的風險。在我們進行研究時,我們發現了3個警示信號對於以嶺藥業(其中1個潛在嚴重!),我們認爲這值得您完全注意。
Today we've zoomed in on a single data point to better understand the nature of Shijiazhuang Yiling Pharmaceutical's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
今天,我們重點關注了一個單一數據點,以更好地了解以嶺藥業利潤的性質。但有很多其他方法可以幫助您了解公司。有些人認爲高股權回報率是質量良好企業的一個好跡象。因此,您可能希望查看這個免費的公司收藏,其中有許多股權回報率高的公司,或者查看這個持有高內部人員股權的股票清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。